Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vlad Ratziu

Showing results (11-20 of 384) with videos related to

Pageof 39
Sort By:
Journal of Hepatology|October 3, 2017
Back to Byzance: Querelles byzantines over NASH and fibrosisVlad Ratziu
The Lancet. Gastroenterology & Hepatology|December 20, 2017
The painful reality of end-stage liver disease in NASHVlad Ratziu
Journal of Hepatology|December 11, 2017
A critical review of endpoints for non-cirrhotic NASH therapeutic trialsVlad Ratziu
Journal of Hepatology|June 16, 2010
Serum fibrosis markers: death by validation or a leap of faith?Vlad Ratziu
Nature Reviews. Gastroenterology & Hepatology|October 16, 2013
Pharmacological agents for NASHVlad Ratziu
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
Non-pharmacological interventions in non-alcoholic fatty liver disease patientsVlad Ratziu
The Lancet. Diabetes & Endocrinology|May 6, 2014
Targeting non-alcoholic fatty liver disease through 11-βHSD1 inhibitionVlad Ratziu
Clinics and Research in Hepatology and Gastroenterology|November 13, 2012
Treatment of NASH with ursodeoxycholic acid: proVlad Ratziu
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 30, 2011
Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?Vlad Ratziu, Loredana Pienar
The New England Journal of Medicine|March 14, 2009
Prolonged therapy for hepatitis C with low-dose peginterferonThierry Poynard, Vlad Ratziu
Pageof 39

Showing results (11-20 of 384) with videos related to

Sort By:
Pageof 39
Journal of Hepatology|October 3, 2017
Back to Byzance: Querelles byzantines over NASH and fibrosisVlad Ratziu
The Lancet. Gastroenterology & Hepatology|December 20, 2017
The painful reality of end-stage liver disease in NASHVlad Ratziu
Journal of Hepatology|December 11, 2017
A critical review of endpoints for non-cirrhotic NASH therapeutic trialsVlad Ratziu
Journal of Hepatology|June 16, 2010
Serum fibrosis markers: death by validation or a leap of faith?Vlad Ratziu
Nature Reviews. Gastroenterology & Hepatology|October 16, 2013
Pharmacological agents for NASHVlad Ratziu
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
Non-pharmacological interventions in non-alcoholic fatty liver disease patientsVlad Ratziu
The Lancet. Diabetes & Endocrinology|May 6, 2014
Targeting non-alcoholic fatty liver disease through 11-βHSD1 inhibitionVlad Ratziu
Clinics and Research in Hepatology and Gastroenterology|November 13, 2012
Treatment of NASH with ursodeoxycholic acid: proVlad Ratziu
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 30, 2011
Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?Vlad Ratziu, Loredana Pienar
The New England Journal of Medicine|March 14, 2009
Prolonged therapy for hepatitis C with low-dose peginterferonThierry Poynard, Vlad Ratziu
Pageof 39